- Lupin will invest $250 million over five years to build a 70,000 sq. ft. pharmaceutical manufacturing facility in Coral Springs, Florida, producing over 25 critical respiratory medicines.
- The project is expected to generate more than 200 long-term, skilled jobs by 2030 and will receive state tax incentives and local support.
Lupin has announced plans to build a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, Florida, with a projected cumulative investment of $250 million over five years. The facility will produce more than 25 critical respiratory medicines, including albuterol inhalers for children with asthma and service members, aiming to strengthen U.S. medicine security and diversify the supply chain.
The new Coral Springs site will expand Lupin’s existing Florida footprint, which includes the company’s headquarters and Advanced Inhalation Research Center. The 70,000 sq. ft. plant is expected to create over 200 skilled, long-term jobs by 2030 in Broward County.
“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida. This investment demonstrates Lupin’s commitment to innovation, quality and supply chain reliability.”
Christoph Funke, Chief Technical Operations Officer of Lupin
The project will be supported through tax credits and incentives from the state of Florida. Lupin is collaborating with Florida Commerce/Select Florida, the City of Coral Springs, Greater Fort Lauderdale Alliance, Broward County Commission, and local workforce partners to ensure successful execution.
“On behalf of FloridaCommerce, I’m excited to welcome Lupin’s expansion in Coral Springs and the high-impact investment it brings to our state.”
Florida Secretary of Commerce J. Alex Kelly
Once operational, the facility will anchor U.S. production of respiratory therapies, provide affordable and reliable access to medicines, and support pandemic-scale demand.
